Endocrine and clinical consequences of combination tamoxifen – aminoglutethimide in postmenopausal breast cancer

Dowsett, Mitch; Harris, Adrian L.; Smith, Ian; Jeffcoate, S. L.

doi:10.1038/bjc.1984.183

Cited by 7 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar rise in SHBG levels with an associated fall in gonadotrophin levels in patients treated with tamoxifen has been attributed to the partial oestrogen agonist activity of tamoxifen (Sakaiet al, I -J 1978;Willis et al, 1977;Coombes et al, 1982;Dowsett et al, 1984). We have not observed a fall in gonadotrophin levels in zindoxifene treated patients.…”

Section: Discussionmentioning

confidence: 44%

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study

Stein

Dowsett²,

Cunningham³

et al. 1990

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary We report a phase I/II study of the indole derivative, zindoxifene, an anti-oestrogen with intrinsic oestrogenic activity. We have treated 28 women with advanced breast cancer of whom 26 had received prior endocrine therapy. Oral zindoxifene doses ranged from 10 to 100 mg daily; doses were escalated in some patients. Twenty-five patients were assessed for response; the remaining three patients completed less than 3 weeks of treatment. There were no objective responses; disease stabilised in seven patients for up to 5 months and progressed in the remaining 18. Five patients (including three treated with tamoxifen) responded to subsequent endocrine therapy. Nausea, which was dose-limiting, affected half of the patients treated with 80 mg daily. Metabolites of zindoxifene were detectable in serum at all doses used, and sex hormone binding globulin (SHBG) levels showed a strong tendency to rise at the higher doses, indicating that zindoxifene is absorbed and has biological activity. We conclude that zindoxifene in the doses used in this study has only marginal therapeutic activity in the treatment of advanced breast cancer.

show abstract

Section: Discussionmentioning

confidence: 44%

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study

Stein

Dowsett²,

Cunningham³

et al. 1990

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…55 The use of HRT 53,56,57 and drugs such as Tamoxifen (adjuvant therapy for breast carcinoma) can also therefore increase the risk of recurrence in the postmenopausal population. [58][59][60][61][62] Postmenopausal endometriosis and HRT Another dilemma in women with endometriosis is the role of HRT in women undergoing radical surgery with bilateral oophorectomies as well as in those going through the natural menopause. As most of the patients undergoing a surgical menopause are young, one needs to carefully consider the benefits of HRT as endometriosis is a hormone-dependent disease and estrogen replacement can be associated with a risk of recurrence or malignant transformation especially in known severe cases and in those that are obese.…”

Section: Endometriosis In Postmenopausal Womenmentioning

confidence: 99%

Section: Endometriosis In Postmenopausal Womenmentioning

confidence: 99%

Endometriosis: associations with menopause, hormone replacement therapy and cancer

Palep-Singh¹,

Gupta²

2009

Menopause International

View full text Add to dashboard Cite

Endometriosis is an estrogen-dependent condition and is characterized by the presence of ectopic endometrial tissue. The pathogenesis of this condition remains an enigma. Endometriosis has well known associations with menopause both in terms of secondary outcomes from medical and surgical therapy in premenopausal women, as well as a natural occurrence/recurrence of the disease in women going through menopause naturally. This review article aims to discuss the current day modalities of management of endometriosis with their pros and cons especially in the context of menopause and cancer.

show abstract

Hormonal effects of toremifene in breast cancer patients

Számel

Vincze

Hindy

et al. 1990

Journal of Steroid Biochemistry

View full text Add to dashboard Cite

Endocrine and clinical consequences of combination tamoxifen – aminoglutethimide in postmenopausal breast cancer

Abstract: Non-responders to this combination therapy had higher levels of oestrone and dehydroepiandrosterone sulphate whilst on treatment than responders, confirming previous observations in patients treated with aminoglutethimide + hydrocortisone.

Cited by 7 publications

References 25 publications

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study

Endometriosis: associations with menopause, hormone replacement therapy and cancer

Hormonal effects of toremifene in breast cancer patients

Contact Info

Product

Resources

About